Salvage lenalidomide in four rare oncological diseases.

Petr Szturz, Zdenek Adam, Zdenek Rehak, Renata Koukalova, Leos Kren, Mojmír Moulis, Marta Krejcí, Jiri Mayer

Journal: Tumori 2014;99(5):e251-6

PMID: 24362880

Abstract

In rare disorders, there are often no standard therapy recommendations. Patients with refractory disease may require novel experimental approaches. Applied as second- up to fourth-line treatment, lenalidomide (10-25 mg perorally on days 1-21 in a 28-day cycle) was used in our cohort of four adult patients with aggressive, multisystem and relapsing diseases. Complete and long-lasting remissions (more than 1 year, no maintenance therapy) were achieved in patients with Langerhans cell histiocytosis (11 cycles, combination with dexamethasone and etoposide, consolidated by allogeneic blood stem cell transplant) and plasma-cell Castleman disease (15 cycles, monotherapy). Mixed response with complete disappearance of brain infiltrates was reached in Erdheim-Chester disease (6 cycles, monotherapy) and gastrointestinal bleeding was well controlled in multiple angiomatosis (9 cycles, combination with thalidomide). For disease activity evaluation each patient underwent fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography scan imaging, which was complemented by clinical and laboratory investigations.

DOI: 10.1177/030089161309900524

Link outs

Free resources

Medical:

https://medlineplus.gov/rarediseases.html

Subscription / membership required

Full Text Sources:

https://journals.sagepub.com/doi/10.1177/030089161...

MeSH Terms: Adult, Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Castleman Disease, Compassionate Use Trials, Disease-Free Survival, Erdheim-Chester Disease, Hematopoietic Stem Cell Transplantation, Histiocytosis, Langerhans-Cell, Humans, Lenalidomide, Magnetic Resonance Imaging, Male, Middle Aged, Positron-Emission Tomography, Rare Diseases, Retrospective Studies, Salvage Therapy, Thalidomide, Tomography, X-Ray Computed, Transplantation, Autologous, Transplantation, Homologous, Treatment Outcome